tcsc0145 Iniparib

Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.

IC50 & Target: PARP1^[3]

In Vitro: Iniparib nonselectively modifies cysteine-containing proteins in tumor cells^[1]. Iniparib (100 μM) weakly inhibits SSB repair, and the inhibition can be reversed by knockdown of PARP1^[2]. Iniparib in combination with cisplatin is cytotoxic to Myc/MDA-231 with EMT changes^[3].